Doravirine/lamivudine/tenofovir disoproxil fumarate

Drug Profile

Doravirine/lamivudine/tenofovir disoproxil fumarate

Alternative Names: MK-1439/lamivudine/tenofovir disoproxil fumarate; MK-1439A

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Nitriles; Phosphonic acids; Purines; Pyridones; Pyrimidine nucleosides; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 09 Nov 2017 Chemical structure added
  • 09 Nov 2017 National Institute of Allergy and Infectious Diseases plans a phase I/II trial for HIV-1 infections (In children, In adolescents) in USA, South Africa and Thailand in March 2018 (NCT03332095)
  • 25 Jul 2017 Merck announces intention to submit NDA to US FDA for HIV-1 infection in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top